Physician profile
Marissa Pierce
NPI 1841749595
$1,325.90
in general payments reported to CMS, 2019-2025
20 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $253 · 2023: $243 · 2024: $441 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.53 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $184.37 | 2022-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $154.75 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $119.02 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Pfizer INC. | $104.48 | 2021-2025 | |
| Novo Nordisk INC | $93.57 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.32 | 2022-2024 | Xifaxan |
| Exact Sciences Corporation | $64.91 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $55.19 | 2021-2025 | |
| Abbott Laboratories | $45.94 | 2024-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $34.34 | 2023-2024 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $23.62 | 2021 | |
| Corium, LLC | $23.07 | 2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $22.34 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.19 | 2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $18.84 | 2022 | |
| Shield Therapeutics INC | $17.56 | 2024 | |
| Corcept Therapeutics | $15.57 | 2022 | |
| Currax Pharmaceuticals LLC | $15.55 | 2022 | |
| Althera Pharmaceuticals LLC | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.